Skip to main content
Top
Published in: Annals of Surgical Oncology 4/2020

01-04-2020 | Esophageal Cancer | Thoracic Oncology

Prognostic Value of Tumor Regression Grade Based on Ryan Score in Squamous Cell Carcinoma and Adenocarcinoma of Esophagus

Authors: Flávio Roberto Takeda, PhD, Francisco Tustumi, MD, Carlos de Almeida Obregon, MD, Gustavo Gonçalves Yogolare, MD, Yasmin Peres Navarro, MD, Vanderlei Segatelli, MD, Rubens Antonio Aissar Sallum, PhD, Ulysses Ribeiro Junior, PhD, Ivan Cecconello, PhD

Published in: Annals of Surgical Oncology | Issue 4/2020

Login to get access

Abstract

Purposes

Tumor regression grade (TRG) of the primary tumor after neoadjuvant therapy is one of the most sensitive prognostic factors among patients with locally advanced esophageal cancer, although no TRG system is fully accepted. The Ryan score was proposed in 2005 to evaluate TRG in rectal cancer and could be adaptable for pathological evaluation of esophageal cancer. The objective of this study is to evaluate the prognostic value of the Ryan score for esophageal cancer in the setting of trimodal therapy.

Methods

We performed a retrospective cohort study in which patients with locally advanced esophageal cancer, submitted to neoadjuvant therapy followed by surgical resection, were selected. One hundred thirty-four patients were selected. All tissue specimens were assessed as per the TRG system proposed by Ryan et al. Survival curves were assessed by the Kaplan–Meier method and log-rank test. Chi-square test or likelihood-ratio test was used for absolute and relative variables. Kruskal–Wallis and analysis of variance tests were used to assess significant differences on a continuous dependent variable by a categorical independent variable.

Results

Of the 134 included patients, 94 (70.1%) had squamous cell carcinoma, and 40 (29.9%) adenocarcinoma. Ryan score was correlated with histological type (p < 0.001), and clinical (p = 0.044) and pathological (p < 0.001) staging. Mean follow-up was 31.1 months. Multivariate analysis showed that Ryan score can safely predict survival, and systemic and lymphatic recurrence (p < 0.05).

Conclusions

Ryan score is an effective system to evaluate TRG and can predict risk for lymph node or distant metastasis, overall survival, and disease-free survival.
Literature
1.
go back to reference Van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.CrossRef Van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.CrossRef
2.
go back to reference Mota FC, Cecconello I, Takeda FR, Tustumi F, Sallum RAA, Bernardo WM. Neoadjuvant therapy or upfront surgery? A systematic review and meta-analysis of T2N0 esophageal cancer treatment options. Int J Surg. 2018;54(Pt A):176–81.CrossRef Mota FC, Cecconello I, Takeda FR, Tustumi F, Sallum RAA, Bernardo WM. Neoadjuvant therapy or upfront surgery? A systematic review and meta-analysis of T2N0 esophageal cancer treatment options. Int J Surg. 2018;54(Pt A):176–81.CrossRef
3.
go back to reference Lerttanatum N, Tharavej C, Chongpison Y, Sanpavat A. Comparison of tumor regression grading system in locally advanced esophageal squamous cell carcinoma after preoperative radio-chemotherapy to determine the most accurate system predicting prognosis. J Gastrointest Oncol. 2019;10(2):276–82.CrossRef Lerttanatum N, Tharavej C, Chongpison Y, Sanpavat A. Comparison of tumor regression grading system in locally advanced esophageal squamous cell carcinoma after preoperative radio-chemotherapy to determine the most accurate system predicting prognosis. J Gastrointest Oncol. 2019;10(2):276–82.CrossRef
4.
go back to reference Andreollo NA, Beraldo GC, Alves IPF, Tercioti-Junior V, Ferrer JAP, Coelho-Neto JS, et al. Pathologic complete response (ypT0 ypN0) after chemotherapy and radiotherapy neoadjuvant followed by esophagectomy in the squamous cell carcinoma of the esophagus. Arq Bras Cir Dig. 2018;31(4):e1405.CrossRef Andreollo NA, Beraldo GC, Alves IPF, Tercioti-Junior V, Ferrer JAP, Coelho-Neto JS, et al. Pathologic complete response (ypT0 ypN0) after chemotherapy and radiotherapy neoadjuvant followed by esophagectomy in the squamous cell carcinoma of the esophagus. Arq Bras Cir Dig. 2018;31(4):e1405.CrossRef
5.
go back to reference Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11):2680–6.CrossRef Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11):2680–6.CrossRef
6.
go back to reference Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103(7):1347–55.CrossRef Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103(7):1347–55.CrossRef
7.
go back to reference Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242(5):684–92.CrossRef Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242(5):684–92.CrossRef
8.
go back to reference Ryan R, Gibbons D, Hyland JM, Treanor D, White A, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005;47(2):141–6.CrossRef Ryan R, Gibbons D, Hyland JM, Treanor D, White A, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005;47(2):141–6.CrossRef
9.
go back to reference Kim SH, Chang HJ, Kim DY, Park JW, Baek JY, Kim SY, et al. What is the ideal tumor regression grading system in rectal cancer patients after preoperative chemoradiotherapy? Cancer Res Treat. 2016;48(3):998–1009.CrossRef Kim SH, Chang HJ, Kim DY, Park JW, Baek JY, Kim SY, et al. What is the ideal tumor regression grading system in rectal cancer patients after preoperative chemoradiotherapy? Cancer Res Treat. 2016;48(3):998–1009.CrossRef
10.
go back to reference Rice TW, Patil DT, Blackstone EH. 8th Edition AJCC/UICC Staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017;6(2):119–30.CrossRef Rice TW, Patil DT, Blackstone EH. 8th Edition AJCC/UICC Staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017;6(2):119–30.CrossRef
11.
go back to reference Takeda FR, Viyuela MS, da Cruz Junior JB, Tustumi F, Braghiroli OFM, Karolyne Ernesto Luiz Nobre KEL, et al. Variables associated to pathologic complete response, overall survival and disease-free survival in the neoadjuvant setting for esophageal cancer: a retrospective cohort analysis. Int Surg. 2018;103:214–21.CrossRef Takeda FR, Viyuela MS, da Cruz Junior JB, Tustumi F, Braghiroli OFM, Karolyne Ernesto Luiz Nobre KEL, et al. Variables associated to pathologic complete response, overall survival and disease-free survival in the neoadjuvant setting for esophageal cancer: a retrospective cohort analysis. Int Surg. 2018;103:214–21.CrossRef
12.
go back to reference Dubben HH, Thames HD, Beck-Bornholdt HP. Tumor volume: a basic and specific response predictor in radiotherapy. Radiother Oncol. 1998;47(2):167–74.CrossRef Dubben HH, Thames HD, Beck-Bornholdt HP. Tumor volume: a basic and specific response predictor in radiotherapy. Radiother Oncol. 1998;47(2):167–74.CrossRef
14.
go back to reference Buckstein M, Rhome R, Ru M, Moshier E. Neoadjuvant chemoradiation radiation dose levels for surgically resectable esophageal cancer: predictors of use and outcomes. Dis Esophagus. 2018;31(5). Buckstein M, Rhome R, Ru M, Moshier E. Neoadjuvant chemoradiation radiation dose levels for surgically resectable esophageal cancer: predictors of use and outcomes. Dis Esophagus. 2018;31(5).
15.
go back to reference van der Werf LR, Dikken JL, van der Willik EM, van Berge Henegouwen MI, Nieuwenhuijzen GAP, Wijnhoven BPL; Dutch Upper Gastrointestinal Cancer Audit (DUCA) group. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: a nationwide study. Eur J Cancer. 2018;91:76-85. van der Werf LR, Dikken JL, van der Willik EM, van Berge Henegouwen MI, Nieuwenhuijzen GAP, Wijnhoven BPL; Dutch Upper Gastrointestinal Cancer Audit (DUCA) group. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: a nationwide study. Eur J Cancer. 2018;91:76-85.
16.
go back to reference Shapiro J, van Hagen P, Lingsma HF, Wijnhoven BP, Biermann K, ten Kate FJ, Steyerberg EW, van der Gaast A, van Lanschot JJ; CROSS Study Group. Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer. Ann Surg. 2014;260(5):807–13; discussion 813–4. Shapiro J, van Hagen P, Lingsma HF, Wijnhoven BP, Biermann K, ten Kate FJ, Steyerberg EW, van der Gaast A, van Lanschot JJ; CROSS Study Group. Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer. Ann Surg. 2014;260(5):807–13; discussion 813–4.
17.
go back to reference Chiu CH, Chao YK, Chang HK, Tseng CK, Chan SC, Liu YH, Chen WH. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome? Ann Surg Oncol. 2013;20:4245–51.CrossRef Chiu CH, Chao YK, Chang HK, Tseng CK, Chan SC, Liu YH, Chen WH. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome? Ann Surg Oncol. 2013;20:4245–51.CrossRef
Metadata
Title
Prognostic Value of Tumor Regression Grade Based on Ryan Score in Squamous Cell Carcinoma and Adenocarcinoma of Esophagus
Authors
Flávio Roberto Takeda, PhD
Francisco Tustumi, MD
Carlos de Almeida Obregon, MD
Gustavo Gonçalves Yogolare, MD
Yasmin Peres Navarro, MD
Vanderlei Segatelli, MD
Rubens Antonio Aissar Sallum, PhD
Ulysses Ribeiro Junior, PhD
Ivan Cecconello, PhD
Publication date
01-04-2020
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 4/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07967-8

Other articles of this Issue 4/2020

Annals of Surgical Oncology 4/2020 Go to the issue